--- title: 'Regulatory Daily Summary: What Happened on October 14, 2026' headline: MHRA plans faster reviews and new AI rules through 2030 description: The UK regulator targets shorter advice and trial-review timelines. The FTC says Martin Shkreli violated his lifetime pharmaceutical-industry ban. url: https://thebench.bio/news/regulatory/2026-10-14 topic: regulatory date: '2026-10-14' covers: - '2026-10-14' date_published: '2026-10-14T12:02:09Z' date_modified: '2026-10-14T12:02:09Z' tags: - Industry - Regulatory sources: 2 publisher: TheBench.Bio --- # Regulatory Daily Summary: What Happened on October 14, 2026 **MHRA plans faster reviews and new AI rules through 2030** The UK regulator targets shorter advice and trial-review timelines. The FTC says Martin Shkreli violated his lifetime pharmaceutical-industry ban. ## Today in brief A new MHRA strategy sets out plans to halve the turnaround for higher-tier scientific advice and shorten initial reviews of qualifying Phase 1 trials. [1] The FTC said Martin Shkreli violated his lifetime ban from the pharmaceutical industry. [2] ## MHRA targets shorter reviews and new rules for AI health tools The Medicines and Healthcare products Regulatory Agency (MHRA) published a strategy for UK oversight of medicines, medical devices, clinical research, and AI-enabled health technologies through 2030. [1] The agency plans to cut the turnaround for higher-tier scientific advice from 90 days to 45, and set a 14-day initial assessment target for qualifying Phase 1 trials. [1] The MHRA plans to use more real-world data and AI analysis to identify possible safety issues sooner, establish a center for AI and digital health, and develop an adaptive framework for AI medical devices. [1] It plans to publish an action plan on AI in medicines development in 2027 and introduce a Women's Health Plan during the year. [1] The strategy also aims to increase diversity in clinical studies, improve patient-centered regulation, and support quicker access to safe treatments, according to the agency. [1] ## The day in numbers - **45 days**: Planned turnaround for the MHRA's higher-tier scientific-advice service, down from 90 days. [1] - **14 days**: Planned initial assessment target for qualifying Phase 1 trials. [1] ## Also published - [Sanofi escapes fine in EU mismarketing case](), pharmaphorum - [FDA new drug approvals in Q3 2026](), Nature Reviews Drug Discovery ## Sources 1. [MHRA 2030 Strategy to modernise patient-centred regulation for the era of AI and personalised medicines](), MHRA, 2026-10-14 2. [FTC says Shkreli is flouting lifetime pharma ban](), pharmaphorum, 2026-10-14 --- TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing. [1]: [2]: